Literature DB >> 15300132

Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

Janice M Rusnak1, Mark G Kortepeter, John Aldis, Ellen Boudreau.   

Abstract

Experience in managing laboratory exposures to potential agents of bioterrorism is limited. The United States Army Medical Research Institute of Infectious Diseases reviewed laboratory exposures involving these agents (1989 to 2002) to assess the effectiveness of medical management. The evaluation of 234 persons (78% vaccinated) for exposure to 289 infectious agents revealed 5 confirmed infections (glanders, Q fever, vaccinia, chikungunya, and Venezuelan equine encephalitis). Postexposure antibiotic prophylaxis was given for most moderate- or high-risk bacterial exposures (41/46; 89%); most unvaccinated minimal-risk (7/10; 70%), and subsets of vaccinated minimal-risk exposures (18/53; 34%) but generally not negligible-risk exposures (6/38; 16%). Vaccine "breakthroughs" were not unexpected (enzootic Venezuelan equine encephalitis, localized vaccinia) or presented with mild symptoms (Q fever). A multifaceted policy of personal protective measures, vaccination, early assessment, and postexposure antibiotic prophylaxis was effective in minimizing morbidity and mortality in at-risk laboratory workers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300132     DOI: 10.1097/01.jom.0000135539.99691.4e

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  9 in total

1.  Interaction of occupational and personal risk factors in workforce health and safety.

Authors:  Paul A Schulte; Sudha Pandalai; Victoria Wulsin; HeeKyoung Chun
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

2.  Risk-based immunization policies and tuberculosis screening practices for animal care and research workers in the United States: survey results and recommendations.

Authors:  Benjamin J Weigler; Donna R Cooper; F Claire Hankenson
Journal:  J Am Assoc Lab Anim Sci       Date:  2012       Impact factor: 1.232

3.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

4.  Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.

Authors:  Emily E Coates; Srilatha Edupuganti; Grace L Chen; Myra Happe; Larisa Strom; Alicia Widge; Maria Burgos Florez; Josephine H Cox; Ingelise Gordon; Sarah Plummer; Abidemi Ola; Galina Yamshchikov; Charla Andrews; Sharon Curate-Ingram; Patricia Morgan; Shashi Nagar; Matthew H Collins; Amy Bray; Thuy Nguyen; Judy Stein; Christopher L Case; Florence Kaltovich; Diane Wycuff; C Jason Liang; Kevin Carlton; Sandra Vazquez; John R Mascola; Julie E Ledgerwood
Journal:  Lancet Infect Dis       Date:  2022-05-11       Impact factor: 71.421

5.  In vitro and in vivo activity of ribavirin against Andes virus infection.

Authors:  David Safronetz; Elaine Haddock; Friederike Feldmann; Hideki Ebihara; Heinz Feldmann
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

6.  Preparing a community hospital to manage work-related exposures to infectious agents in BioSafety level 3 and 4 laboratories.

Authors:  George F Risi; Marshall E Bloom; Nancy P Hoe; Thomas Arminio; Paul Carlson; Tamara Powers; Heinz Feldmann; Deborah Wilson
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

7.  Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit.

Authors:  Mark G Kortepeter; James W Martin; Janice M Rusnak; Theodore J Cieslak; Kelly L Warfield; Edwin L Anderson; Manmohan V Ranadive
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

Review 8.  Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases.

Authors:  Barbara Bannister; Vincenzo Puro; Francesco Maria Fusco; Julia Heptonstall; Giuseppe Ippolito
Journal:  Lancet Infect Dis       Date:  2009-01       Impact factor: 25.071

9.  The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity.

Authors:  Maryam Keshtkar-Jahromi; Ronald B Reisler; Jeannine M Haller; Denise P Clizbe; Robert G Rivard; Anthony P Cardile; Benjamin C Pierson; Sarah Norris; David Saunders; Phillip R Pittman
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.